Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.

A pilot study to determine whether methotrexate has anti-inflammatory activity in refractory inflammatory bowel disease found that 16 of twenty-one patients had an objective response as measured by disease activity indices, and further work is needed before the drug can be recommended forinflammatory bowel disease.